Influenza virus vaccine (rNA) - Protein Sciences
Alternative Names: FluNhance; rNALatest Information Update: 23 Sep 2021
At a glance
- Originator Protein Sciences Corporation
- Developer National Institute of Allergy and Infectious Diseases; Protein Sciences Corporation
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 28 Aug 2017 Protein Sciences Corporation has been acquired by Sanofi
- 06 Aug 2015 Phase-II development is ongoing in USA
- 12 Sep 2005 Profile reviewed with information available at the BIO-2005 Conference